The global biopharmaceutical excipients market size was estimated at USD 3.18 billion in 2025 and is projected to reach USD 4.97 billion by 2033, growing at a CAGR of 5.79% from 2026 to 2033. The industry is growing due to the rapid expansion of biologic drugs such as monoclonal antibodies, vaccines, recombinant proteins, and gene and cell therapies.
These complex molecules require high-quality excipients to ensure stability, safety, and effective drug delivery. Increasing investments in biopharmaceutical research and development, along with a strong pipeline of biologics and biosimilars, are significantly boosting demand. Advances in formulation technologies, including injectable, sustained release, and nanoparticle-based systems, further support market growth. In addition, the rising prevalence of chronic and rare diseases is increasing reliance on biologic therapies. Strict regulatory requirements for product quality and purity are also driving the adoption of specialized, high-performance excipients across global biopharmaceutical manufacturing.
Rapid growth in biopharmaceutical therapeutics, particularly monoclonal antibodies, vaccines, biosimilars, and cell/gene therapies, directly propels the biopharmaceutical excipients market by necessitating advanced stabilizers, buffers, and surfactants to address the inherent instability of these complex biologics. Proteins and viral vectors are prone to aggregation, denaturation, and loss of efficacy during manufacturing, storage, and delivery, making excipients essential for maintaining higher-order structure, solubility, and bioavailability. This demand boost as pipelines expand, with each new therapeutic requiring tailored formulations, such as sugars for cryoprotection, amino acids for viscosity control, and polymers for targeted delivery, that go beyond inert fillers to enable scalable production and clinical success.
The surge in approvals underscores this linkage: in 2024, the FDA greenlit around eight to nine cell and gene therapies, including CAR-T products like lifileucel (Amtagvi) for melanoma and Casgevy for sickle cell disease, each demanding specialized excipients for vector stability, freeze-thaw resilience, and transduction efficiency. Similarly, monoclonal antibodies and biosimilars continue to dominate new approvals, with formulations relying on surfactants to mitigate interfacial stress and polyols to ensure long-term shelf life, thereby amplifying recurring needs in parenteral and cold-chain logistics. These instances highlight how biologic complexity drives innovation in excipient science, from high-concentration injectables to nanoparticle systems.
The biopharmaceutical industry has significantly increased R&D spending on advanced therapeutic classes, including monoclonal antibodies, mRNA vaccines, gene therapies, and cell therapies, with a growing emphasis on formulation science at early development stages. As biologics become more complex and delivery-dependent, demand is increasing for specialized excipients that can stabilize sensitive molecules and facilitate targeted, efficient delivery. In 2025, this trend was characterized by Mount Sinai researchers developing a “smarter” mRNA therapy designed to activate only in specific target cells, highlighting the industry’s shift toward precision mRNA platforms. Such innovations inherently rely on advanced formulation systems, particularly optimized lipid and polymer excipients, to protect mRNA, control release, and ensure cellular uptake. Alongside this, biotech companies advancing next-generation mRNA vaccines and therapeutic mRNA programs are investing heavily in formulation platforms that go beyond first-generation lipid nanoparticles used during the COVID-19 era. Collectively, these R&D investments are accelerating the development and adoption of high-performance excipients tailored to emerging biopharmaceutical modalities, thereby driving growth in the global market.
Similarly, innovations such as those in June 2025, Ashland’s expanded Viatel bioresorbable polymers demonstrate how specialized excipient technologies are evolving to meet the formulation and delivery challenges posed by modern biologics, including long-acting injectables and advanced mRNA therapies. This expansion highlights the increasing R&D and commercial focus on high-performance excipient platforms that enhance stability, control release, and enable new delivery modalities, thereby further driving growth in the industry.
These complex molecules require high-quality excipients to ensure stability, safety, and effective drug delivery. Increasing investments in biopharmaceutical research and development, along with a strong pipeline of biologics and biosimilars, are significantly boosting demand. Advances in formulation technologies, including injectable, sustained release, and nanoparticle-based systems, further support market growth. In addition, the rising prevalence of chronic and rare diseases is increasing reliance on biologic therapies. Strict regulatory requirements for product quality and purity are also driving the adoption of specialized, high-performance excipients across global biopharmaceutical manufacturing.
Rapid growth in biopharmaceutical therapeutics, particularly monoclonal antibodies, vaccines, biosimilars, and cell/gene therapies, directly propels the biopharmaceutical excipients market by necessitating advanced stabilizers, buffers, and surfactants to address the inherent instability of these complex biologics. Proteins and viral vectors are prone to aggregation, denaturation, and loss of efficacy during manufacturing, storage, and delivery, making excipients essential for maintaining higher-order structure, solubility, and bioavailability. This demand boost as pipelines expand, with each new therapeutic requiring tailored formulations, such as sugars for cryoprotection, amino acids for viscosity control, and polymers for targeted delivery, that go beyond inert fillers to enable scalable production and clinical success.
The surge in approvals underscores this linkage: in 2024, the FDA greenlit around eight to nine cell and gene therapies, including CAR-T products like lifileucel (Amtagvi) for melanoma and Casgevy for sickle cell disease, each demanding specialized excipients for vector stability, freeze-thaw resilience, and transduction efficiency. Similarly, monoclonal antibodies and biosimilars continue to dominate new approvals, with formulations relying on surfactants to mitigate interfacial stress and polyols to ensure long-term shelf life, thereby amplifying recurring needs in parenteral and cold-chain logistics. These instances highlight how biologic complexity drives innovation in excipient science, from high-concentration injectables to nanoparticle systems.
The biopharmaceutical industry has significantly increased R&D spending on advanced therapeutic classes, including monoclonal antibodies, mRNA vaccines, gene therapies, and cell therapies, with a growing emphasis on formulation science at early development stages. As biologics become more complex and delivery-dependent, demand is increasing for specialized excipients that can stabilize sensitive molecules and facilitate targeted, efficient delivery. In 2025, this trend was characterized by Mount Sinai researchers developing a “smarter” mRNA therapy designed to activate only in specific target cells, highlighting the industry’s shift toward precision mRNA platforms. Such innovations inherently rely on advanced formulation systems, particularly optimized lipid and polymer excipients, to protect mRNA, control release, and ensure cellular uptake. Alongside this, biotech companies advancing next-generation mRNA vaccines and therapeutic mRNA programs are investing heavily in formulation platforms that go beyond first-generation lipid nanoparticles used during the COVID-19 era. Collectively, these R&D investments are accelerating the development and adoption of high-performance excipients tailored to emerging biopharmaceutical modalities, thereby driving growth in the global market.
Similarly, innovations such as those in June 2025, Ashland’s expanded Viatel bioresorbable polymers demonstrate how specialized excipient technologies are evolving to meet the formulation and delivery challenges posed by modern biologics, including long-acting injectables and advanced mRNA therapies. This expansion highlights the increasing R&D and commercial focus on high-performance excipient platforms that enhance stability, control release, and enable new delivery modalities, thereby further driving growth in the industry.
Global Biopharmaceutical Excipients Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global biopharmaceutical excipients market report based on product, material, dosage form, therapeutic modality, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Solubilizes & Surfactants/Emulsifiers
- Polyols
- Carbohydrates
- Specialty Excipients
Material Outlook (Revenue, USD Million, 2021-2033)
- Sugars & Polyols
- Polymers
- Amino Acids
- Inorganic Salts & Buffers
- Specialty Co-Processed Excipients / Novel Excipients
Dosage Form Outlook (Revenue, USD Million, 2021-2033)
- Parenteral (Liquid injectables)
- Lyophilized (Freeze-dried)
- Others
Therapeutic Modality Outlook (Revenue, USD Million, 2021-2033)
- Monoclonal Antibodies
- Recombinant Proteins & Enzymes
- Vaccines
- Cell & Gene Therapy Formulations
- Peptides & Oligonucleotides
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Biopharmaceutical Excipients Market Variables, Trends, & Scope
Chapter 4. Biopharmaceutical Excipients Market: Product Business Analysis
Chapter 5. Biopharmaceutical Excipients Market: Material Business Analysis
Chapter 6. Biopharmaceutical Excipients Market: Dosage Form Business Analysis
Chapter 7. Biopharmaceutical Excipients Market: Therapeutic Modality Business Analysis
Chapter 8. Biopharmaceutical Excipients Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this Biopharmaceutical Excipients market report include:- Merck KGaA
- Colorcon
- BASF SE
- Associated British Foods plc
- Signet Excipients Pvt. Ltd (IMCD)
- Sigachi Industries Limited
- Spectrum Chemical Manufacturing Corp.
- Roquette Frères
- IMCD
- Clariant
- DFE Pharma
- J. RETTENMAIER & SÖHNE GmbH + Co KG
- Evonik Industries AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | January 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 3.18 Billion |
| Forecasted Market Value ( USD | $ 4.97 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
